We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
Sanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with inadequately controlled CRSwNP, if approved by the FDA.
The tech firm and the stock are proven winners. Now might be the time for investors to heed tried-and-true investment advice and buy Veeva while others are fearful.
bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.
Pfizer (PFE) reports the death of a participant in a mid-stage study of its Duchenne drug. An FDA panel meeting to discuss Eli Lilly's (LLY) donanemab is set to take place on Jun 10.
Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.
Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Guidance lifts are among the most positive announcements shareholders can hear, injecting confidence in the long-term picture. And that's precisely what these three companies have recently announced.
TEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for sales. It announces promising data from a phase III study on schizophrenia candidate, olanzapine.
CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.
Dr. Reddy's (RDY) posts better-than-expected fiscal fourth-quarter results on growth in global generics revenues in North America as well as Emerging Markets.
Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.
pharmaceuticals: Archive
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
by Zacks Equity Research
Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
AZNPositive Net Change BMYPositive Net Change MRKNegative Net Change LGNDNegative Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
by Zacks Equity Research
Sanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with inadequately controlled CRSwNP, if approved by the FDA.
REGNPositive Net Change SNYPositive Net Change LGNDNegative Net Change ANIPNegative Net Change
pharmaceuticals
Bull of the Day: Veeva Systems (VEEV)
by Benjamin Rains
The tech firm and the stock are proven winners. Now might be the time for investors to heed tried-and-true investment advice and buy Veeva while others are fearful.
VEEVPositive Net Change
biotechnology pharmaceuticals tech-stocks
Top Stock Reports for Amazon.com, Visa & Pfizer
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Visa Inc. (V) and Pfizer Inc. (PFE).
AMZNNegative Net Change VNegative Net Change PFEPositive Net Change MLMNegative Net Change TRPNo Net Change ZBHNegative Net Change
business-services pharmaceuticals retail
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
by Zacks Equity Research
bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.
VRTXPositive Net Change HTGCNegative Net Change BLUENegative Net Change CRSPPositive Net Change
biotechs earnings gene-therapy pharmaceuticals
Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
by Kinjel Shah
Pfizer (PFE) reports the death of a participant in a mid-stage study of its Duchenne drug. An FDA panel meeting to discuss Eli Lilly's (LLY) donanemab is set to take place on Jun 10.
PFEPositive Net Change MRKNegative Net Change LLYNegative Net Change
pharmaceuticals
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
by Zacks Equity Research
Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.
LGNDNegative Net Change FOLDNegative Net Change ANIPNegative Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.
NBIXNegative Net Change ANIPNegative Net Change XENENegative Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
3 Stocks to Buy Following Guidance Upgrades
by Derek Lewis
Guidance lifts are among the most positive announcements shareholders can hear, injecting confidence in the long-term picture. And that's precisely what these three companies have recently announced.
LLYNegative Net Change ETNNegative Net Change ANETNegative Net Change
artificial-intelligence electronics medical pharmaceuticals tech-stocks
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
by Zacks Equity Research
TEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for sales. It announces promising data from a phase III study on schizophrenia candidate, olanzapine.
JNJPositive Net Change TEVAPositive Net Change LGNDNegative Net Change ABBVPositive Net Change
pharmaceuticals
Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses
by Zacks Equity Research
Prothena (PRTA) posts a wider-than-expected loss in the first quarter on lower revenues and higher costs.
RHHBYNegative Net Change BMYPositive Net Change NVOPositive Net Change PRTANegative Net Change
biotechnology biotechs earnings pharmaceuticals
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
by Zacks Equity Research
Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.
LGNDNegative Net Change CPRXPositive Net Change ANIPNegative Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down
by Zacks Equity Research
Viatris (VTRS) Q1 numbers fall short of estimates. The company adjusts the annual guidance to reflect the impact of divestitures.
LGNDNegative Net Change ANIPNegative Net Change BBIONegative Net Change VTRSPositive Net Change
earnings medical pharmaceuticals
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.
VRTXPositive Net Change UTHRPositive Net Change LGNDNegative Net Change CRSPPositive Net Change
biotechs cell-therapy crispr earnings gene-editing gene-therapy immuno-therapy medical pharmaceuticals
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.
LGNDNegative Net Change ANIPNegative Net Change ACADNegative Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
LGNDNegative Net Change ANIPNegative Net Change ITCIPositive Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports first-quarter 2024 results, wherein earnings miss but revenues beat estimates, driven by Exparel sales.
LGNDNegative Net Change PCRXPositive Net Change ANIPNegative Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Ionis (IONS) posts mixed first-quarter 2024 results. The company continues to focus on pipeline development.
AZNPositive Net Change NVSPositive Net Change BIIBPositive Net Change IONSNegative Net Change
pharmaceuticals
Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow
by Zacks Equity Research
Dr. Reddy's (RDY) posts better-than-expected fiscal fourth-quarter results on growth in global generics revenues in North America as well as Emerging Markets.
RDYPositive Net Change LGNDNegative Net Change ANIPNegative Net Change BBIONegative Net Change
earnings medical pharmaceuticals
Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus
by Zacks Equity Research
Denali (DNLI) Q1 loss narrows year over year due to lower expenses despite nil revenues.
SNYPositive Net Change BIIBPositive Net Change LGNDNegative Net Change DNLIPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Bear of the Day: CVS Health (CVS)
by Jeremy Mullin
CVS continues to face headwinds amidst growth challenges.
CVSPositive Net Change WBAPositive Net Change
pharmaceuticals retail
Q1 Earnings Season Scorecard and Fresh Analyst Reports for Tesla, JNJ & Netflix
by Sheraz Mian
Today's Research Daily features the Q1 earnings season scorecard and updated analyst reports on Tesla (TSLA), JNJ (JNJ), Netflix (NFLX) and others.
ABTPositive Net Change JNJPositive Net Change COPNegative Net Change NFLXPositive Net Change TSLAPositive Net Change TTEPositive Net Change
auto-tires-trucks consumer-discretionary pharmaceuticals
A Look at Pharma ETFs Post Q1 Earnings
by Sweta Killa
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
BMYPositive Net Change JNJPositive Net Change MRKNegative Net Change LLYNegative Net Change PJPPositive Net Change IHEPositive Net Change XPHPositive Net Change PPHPositive Net Change FTXHPositive Net Change
earnings etfs pharmaceuticals
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.
LGNDNegative Net Change ANIPNegative Net Change APLSPositive Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.
ANIPNegative Net Change ADVMNegative Net Change ARVNPositive Net Change ABSIPositive Net Change
biotechnology biotechs pharmaceuticals